Low‐dose‐rate brachytherapy for prostate cancer: outcomes at >10 years of follow‐up

Abstract

LDR-BT yields excellent survival rates, with a 17-year PCSS rate of 97%. In all, 18% of patients with biochemical relapse failed at >10 years after implantation, which justifies their continued follow-up.